Progression of subclinical cardiovascular disease in patients with HIV

CONCLUSIONS: After six years of follow-up, an increase in SCORE2, carotid plaques, CAC scoring and MESA risk was observed. MDCT findings, along with other clinical and laboratory parameters, could play an important role as a marker of CVD progression in the evaluation of patients with HIV and low cardiovascular risk.PMID:38682819 | DOI:10.37201/req/033.2024

Source: Revista Espanola de Quimioterapia - April 29, 2024 Category: Drugs & Pharmacology Authors: M Fayos F Arnaiz de Las Revillas V Gonz ález Quintanilla C Gonz ález-Rico C Fari ñas-Álvarez J A Parra M C Fari ñas Source Type: research